vTv Therapeutics (FRA:5VT0) Cyclically Adjusted Book per Share: €-132.16 (As of Mar. 2026)


FRA:5VT0 vTv Therapeutics Inc FRA:5VT0
35 GF Score
Price €31.20
GF Value €6,488.10
! 1 Warning Sign
View Full Analysis

What is vTv Therapeutics Cyclically Adjusted Book per Share?

vTv Therapeutics FRA:5VT0 +3.31% 35 Cyclically Adjusted Book per Share is €-132.16 as of Mar. 2026. GuruFocus rates FRA:5VT0 with a GF Score™ of 35/100 and a GF Value™ of €6,488.10. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

vTv Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €19.755. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €-132.16 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-01), vTv Therapeutics's current stock price is €31.20. vTv Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €-132.16. vTv Therapeutics's Cyclically Adjusted PB Ratio of today is .


vTv Therapeutics  (FRA:5VT0) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


vTv Therapeutics Cyclically Adjusted Book per Share Related Terms


vTv Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for vTv Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

vTv Therapeutics Cyclically Adjusted Book per Share Chart

vTv Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -235.58 -198.23 -136.26

vTv Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -194.03 -163.29 -152.97 -136.26 -132.16

FRA:5VT0 vs SMNR, CNTB, ENLV: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, vTv Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


vTv Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where vTv Therapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:5VT0
35GF Score
vTv Therapeutics Inc FRA:5VT0
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

vTv Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, vTv Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=19.755/330.2130*330.2130
=19.755

Current CPI (Mar. 2026) = 330.2130.

vTv Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 -292.450 241.018 -400.679
201609 -409.566 241.428 -560.184
201612 -356.264 241.432 -487.272
201703 -477.041 243.801 -646.122
201706 -391.343 244.955 -527.552
201709 -472.554 246.819 -632.218
201712 -527.417 246.524 -706.462
201803 -496.572 249.554 -657.070
201806 -225.320 251.989 -295.265
201809 -95.657 252.439 -125.128
201812 -143.081 251.233 -188.061
201903 -75.029 254.202 -97.464
201906 -59.200 256.143 -76.319
201909 -48.319 256.759 -62.142
201912 -43.129 256.974 -55.421
202003 -50.088 258.115 -64.079
202006 -51.494 257.797 -65.959
202009 -35.488 260.280 -45.023
202012 -48.737 260.474 -61.786
202103 -32.850 264.877 -40.953
202106 -26.374 271.696 -32.054
202109 -11.019 274.310 -13.265
202112 -5.149 278.802 -6.098
202203 -4.389 287.504 -5.041
202206 -4.173 296.311 -4.650
202209 -8.216 296.808 -9.141
202212 -4.977 296.797 -5.537
202303 -8.800 301.836 -9.627
202306 -11.456 305.109 -12.399
202309 -11.607 307.789 -12.453
202312 -10.855 306.746 -11.685
202403 7.864 312.332 8.314
202406 6.291 314.175 6.612
202409 5.177 315.301 5.422
202412 4.460 315.605 4.666
202503 2.805 319.799 2.896
202506 0.915 322.561 0.937
202509 15.262 324.800 15.516
202512 13.970 324.054 14.236
202603 19.755 330.213 19.755

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €-132.16 mean?
vTv Therapeutics (FRA:5VT0) has a Cyclically Adjusted Book per Share of €-132.16 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on vTv Therapeutics and its competitors.
Is vTv Therapeutics' Cyclically Adjusted Book per Share too high?
vTv Therapeutics' current Cyclically Adjusted Book per Share is €-132.16. Overall, vTv Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' Cyclically Adjusted Book per Share compare to SMNR and CNTB?
vTv Therapeutics' Cyclically Adjusted Book per Share of €-132.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on vTv Therapeutics and its competitors. vTv Therapeutics's current Cyclically Adjusted Book per Share is €-132.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (FRA:5VT0) has a current Cyclically Adjusted Book per Share of €-132.16. The stock's GF Value™ is €6,488.10, compared to a current price of €31.20 — trading 99.5% below its estimated fair value. The current Cyclically Adjusted Book per Share is €-132.16. vTv Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current Cyclically Adjusted Book per Share is €-132.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?

Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued. The current stock price of €31.20 is trading 99.5% below its estimated GF Value™ of €6,488.10.

Key valuation signals for FRA:5VT0:

  • Cyclically Adjusted Book per Share: €-132.16
  • GF Value™: €6,488.10 vs. price of €31.20 (99.5% below fair value)
  • GF Score™: 35/100 with 1 warning sign

No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


vTv Therapeutics Business Description

Other Exchanges VTVT:USA
Address 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score

Get the complete analysis for FRA:5VT0

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€31.20
Price
€6,488.10
GF Value